Amendment 6 to Patent License Agreement between Kura Oncology, Inc. and The Regents of the University of Michigan
Kura Oncology, Inc. is notifying The Regents of the University of Michigan that it is exercising its option to obtain an exclusive, royalty-bearing license to a specific University patent application, as allowed under their existing Research Agreement. This notice serves as Amendment 6 to their Patent License Agreement, officially adding the referenced patent application to the agreement's definition of patent rights. The amendment is effective immediately upon this notice.
Exhibit 10.23
***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
VIA CERTIFIED MAIL
August 24, 2017
The Regents of the University of Michigan
Office of Research and Sponsored Projects
3003 S. State St. Room 1070
Ann Arbor, MI 48109-1274
Attn: Anthony L. Neilsen, J.D.
| RE: | Research Agreement between Kura Oncology, Inc. (“Kura”) and The Regents of the University of Michigan (the “University”) dated February 15, 2015 (the “Research Agreement”) |
| (Amendment 6 to the Patent License Agreement dated December 22, 2014) |
Dear Anthony:
Pursuant to Section 8.2 of the Research Agreement, we hereby give notice of the exercise by Kura of its option to obtain an exclusive royalty-bearing license to the University’s interest in the patent application numbered […***…]. Effective upon this notice, the Patent License Agreement between the University and Kura is deemed amended (Amendment 6) to add the above-referenced patent application to subsection (ii)(a) of the definition of PATENT RIGHTS under such agreement.
Please let me know if you have any questions.
Sincerely,
/s/ Annette North
Annette North
SVP, General Counsel
cc: Ed Pagani, Ph.D., Associate Director,
University of Michigan
***Confidential Treatment Requested
3033 Science Park Road, Suite 220, San Diego, CA 92121
